United Therapeutics Co. (NASDAQ:UTHR) Holdings Lowered by Russell Investments Group Ltd.

Russell Investments Group Ltd. lessened its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 12.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 116,338 shares of the biotechnology company’s stock after selling 16,450 shares during the period. Russell Investments Group Ltd. owned about 0.25% of United Therapeutics worth $25,682,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. BlackRock Inc. lifted its position in shares of United Therapeutics by 5.4% in the 1st quarter. BlackRock Inc. now owns 4,751,961 shares of the biotechnology company’s stock valued at $1,064,249,000 after acquiring an additional 241,594 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of United Therapeutics by 47.2% during the 1st quarter. Wellington Management Group LLP now owns 3,781,840 shares of the biotechnology company’s stock worth $846,981,000 after purchasing an additional 1,212,577 shares during the last quarter. State Street Corp lifted its position in shares of United Therapeutics by 15.9% in the first quarter. State Street Corp now owns 1,795,102 shares of the biotechnology company’s stock worth $402,031,000 after buying an additional 245,747 shares during the last quarter. Geode Capital Management LLC boosted its position in United Therapeutics by 14.9% during the first quarter. Geode Capital Management LLC now owns 759,143 shares of the biotechnology company’s stock worth $169,811,000 after purchasing an additional 98,267 shares during the period. Finally, Farallon Capital Management LLC raised its holdings in United Therapeutics by 1.4% in the 1st quarter. Farallon Capital Management LLC now owns 664,767 shares of the biotechnology company’s stock worth $148,881,000 after acquiring an additional 8,894 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $225.76, for a total value of $1,354,560.00. Following the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at $8,262,590.24. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $225.76, for a total transaction of $1,354,560.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at approximately $8,262,590.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nilda Mesa sold 383 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $222.36, for a total value of $85,163.88. Following the sale, the director now owns 6,303 shares in the company, valued at approximately $1,401,535.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,383 shares of company stock valued at $6,806,244. 12.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Morgan Stanley dropped their price objective on United Therapeutics from $318.00 to $314.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $256.00 to $268.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 10th. JPMorgan Chase & Co. boosted their price objective on shares of United Therapeutics from $290.00 to $294.00 and gave the stock an “overweight” rating in a report on Thursday, November 2nd. Finally, Wedbush restated an “outperform” rating and set a $308.00 price target (up from $307.00) on shares of United Therapeutics in a research note on Thursday, November 2nd. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $288.00.

United Therapeutics Stock Up 0.0 %

Shares of UTHR opened at $228.99 on Tuesday. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $283.09. The stock has a market cap of $10.76 billion, a price-to-earnings ratio of 12.62 and a beta of 0.57. The company has a 50-day moving average price of $226.19 and a two-hundred day moving average price of $225.97. The company has a quick ratio of 4.51, a current ratio of 4.65 and a debt-to-equity ratio of 0.09.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported $5.38 EPS for the quarter, beating the consensus estimate of $5.10 by $0.28. United Therapeutics had a return on equity of 17.10% and a net margin of 40.82%. The business had revenue of $609.40 million for the quarter, compared to analyst estimates of $585.82 million. During the same quarter in the previous year, the firm earned $4.91 EPS. United Therapeutics’s quarterly revenue was up 18.1% on a year-over-year basis. Equities analysts predict that United Therapeutics Co. will post 19.36 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.